お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
758935

市場競争分析:HIV (ヒト免疫不全ウイルス)

Competitor Landscape: HIV

出版日: | 発行: GlobalData | ページ情報: 英文 68 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.27円
市場競争分析:HIV (ヒト免疫不全ウイルス)
出版日: 2018年10月31日
発行: GlobalData
ページ情報: 英文 68 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、HIV (ヒト免疫不全ウイルス) 治療薬の開発状況と市場競争の見通しについて分析し、主要企業の最新情勢や将来展望、今後の事業展開の方向性 (市場参入など)、主なパイプライン製品/認証済み製品の概略と治験の進展見通し、現在/将来の製品ポジショニングなどについて調査しております。

イントロダクション

エグゼクティブ・サマリー

  • 近年の市場の主な出来事と今後の動向見通し
  • 治験のマイルストーン (最新版)

市場情勢

  • 市場参入/製品上市の見通し
  • 主要企業の市場参入戦略
  • ライフサイクル管理の動向
  • 主要企業の「進行方向」

パイプライン製品の治験状況

  • パイプライン製品の概略
  • 近年の市場動向と今後のマイルストーン (2018~19年)

認証済み製品の治験状況

  • ライフサイクル管理の動向

付録

目次
Product Code: GDHC073SP

Summary

Competitor Landscape: HIV", briefings contain evaluations of ongoing development activities within the Human Immunodeficiency Virus (HIV) disease market, together with analysis of current & potential future product positioning.

Key Highlights from the report

  • Doravirine (approved in the US in Aug 2018) provides a tolerable NNRTI option with a high barrier to resistance, and is expected be used as part of multi-pill triple combinations where it may replace older NNRTIs.
  • If approved, ibalizumab would be the first biologic and first long-acting HIV drug in the EU, and would provide an option for patients with multidrug-resistant HIV infection which represents a population with a high unmet need.
  • While Frontier Biotech received China approval for albuvirtide for the treatment of HIV in Jun 2018, its FDA approved IND for a Phase II trial of albuvirtide + 3BNC117 is the first indication of clinical activity in the US.
Competitor Landscape: Human Immunodeficiency Virus (HIV) report comprises five key sections. Executive Summary: Contains analysis of key market events that have occurred during the previous month and which have impacted the HIV landscape.

Landscape Updates

  • 'Order of Entry' analysis, detailing timeline forecasts for each drug in Phase II development or higher.
  • Timeline forecasts for each approved product's lifecycle management initiatives.
  • 'Market Entry' & 'Direction of Travel' positioning analysis for pipeline & currently approved therapies.

Pipeline Landscape

  • An overview of pipeline candidates, containing snapshots of current development status.
  • Expected drug-specific events & milestones until YE 2021.
Approved Product Landscape: An overview of approved drugs, containing snapshots of current development status.

Appendix

  • Current early stage HIV pipeline & candidate 'Watch List'.
  • Timeline assumptions, including standard assumptions & drug-specific assumptions.

Scope

  • The briefing is based on Sociable Pharma's analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov)
  • Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher - these are outlined in the report Appendix
  • Forecasts are presented in pipeline forecast figures & detailed tables
  • 'Market Entry' & 'Direction of Travel' positioning analysis for pipeline & currently approved therapies is also provided.

Reasons to buy

  • Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher
  • Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market
  • Reviews ongoing lifecycle management strategies for existing players in the market
  • A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts.

Table of Contents

Introduction to Sociable Pharma's HIV 'Competitor Landscape'

Executive Summary

  • Key Events & Landscape Updates
  • Updated Milestones

Landscape Updates

  • Order of Entry
  • Key Competitor Market Entry Strategies
  • Lifecycle Development
  • Key Competitor 'Direction of Travel'

Pipeline Landscape

  • Pipeline Summary
  • Events & Milestones: 2018-19

Approved Product Development Landscape

  • Lifecycle Development

Appendix

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.